SCHEMBL6505251

SCHEMBL6505251

CCOC(=O)N1CCC(C(CC(=O)OC)NC(=O)OCc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP2C19 P33261 1/20 0.48
CCR1 P32246 1/20 0.46
CTSK P43235 3/20 0.45
CTSL P07711 2/20 0.45
CTSB P07858 2/20 0.45
CTSS P25774 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
BCHE P06276 2/20 0.45
ACHE P22303 2/20 0.45
DPP4 P27487 1/20 0.45
KCNH2 Q12809 1/20 0.45
DPP7 Q9UHL4 1/20 0.45
CACNA1F O60840 1/20 0.45
CACNA1D Q01668 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1072889 0.87 GPR119 (0.52) HTTL3MBTL1BCHEACHE
SCHEMBL23011527 0.84 KMT2A (0.59) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL8140327 0.83 CTSK (0.48) SMN1; SMN2MEN1KMT2ACYP2C19CTSK
SCHEMBL1018362 0.81 ITGB3 (0.46) CYP2C19CTSKCTSLCTSBCTSS
SCHEMBL6505256 0.79 SMN1; SMN2 (0.52) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL20660513 0.78 GPR119 (0.55) HTTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL20660188 0.78 GPR119 (0.55) HTTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL20660441 0.78 GPR119 (0.55) HTTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL20660300 0.78 DPP4 (0.49) SMN1; SMN2NPC1RAB9ACYP2C19CCR1
SCHEMBL7132652 0.77 SMN1; SMN2 (0.65) HTTSMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US disclosed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB HTT 3685/4885SMN1; SMN2 4664/4885NPC1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.